Novelos Therapeutics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Novelos therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Novelos Therapeutics Today - Breaking & Trending Today

Anumana Appoints Harry S. Palmin as CFO

Anumana Appoints Harry S. Palmin as CFO
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United States , Nandans Anavekar , Maulik Nanavaty , Jaskanwald Sara , Amir Lerman , Bernardj Gersh , Takumi Toya , Harrys Palmin , International Business School At Brandeis University , Copenhagen Business School , Heart Failure Population Health , Acer Therapeutics Inc , American Medical Association , Novelos Therapeutics Inc , London School Of Economics , Banner Health , Vanderbilt University Medical Center , Zevra Therapeutics Inc , Duke Health , Appoints Harry , Zevra Therapeutics , Novelos Therapeutics , Tech Breakthrough Award , New Technology , International Business School , London School ,

Cellectar Biosciences (NASDAQ:CLRB) Downgraded to "Hold" at Zacks Investment Research

Cellectar Biosciences (NASDAQ:CLRB – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday, Zacks.com reports. According to Zacks, “Cellectar Biosciences, Inc. is developing agents to detect, treat and monitor a broad spectrum of cancers. It uses a […] ....

United States , Cellectar Biosciences , Morgan Stanley , Geode Capital Management , Zacks Investment Research , Novelos Therapeutics Inc , Cellectar Biosciences Inc , Worth Venture Partners , Franklin Resources Inc , Maxim Group , Capital Management , Get Rating , Biosciences Inc , Novelos Therapeutics , Venture Partners , Nasdaq Clrb ,

Research Analysts' Weekly Ratings Changes for Cellectar Biosciences (CLRB)

Several analysts have recently updated their ratings and price targets for Cellectar Biosciences (NASDAQ: CLRB): 5/29/2022 – Cellectar Biosciences is now covered by analysts at StockNews.com. They set a “sell” rating on the stock. 5/26/2022 – Cellectar Biosciences had its price target lowered by analysts at Maxim Group to $1.25. 5/24/2022 – Cellectar Biosciences was […] ....

United States , Cellectar Biosciences , Morgan Stanley , Geode Capital Management , Zacks Investment Research , Novelos Therapeutics Inc , Cellectar Biosciences Inc , Worth Venture Partners , Franklin Resources Inc , Maxim Group , Capital Management , Biosciences Inc , Novelos Therapeutics , Get Rating , Venture Partners , Nasdaq Clrb ,

Equities Research Analysts' Updated EPS Estimates for May 24th (CENTA, CGC, CHCT, CLGN, CLRB, CMPO, CORZ, CRDL, CRH, CRHKY)

Equities Research Analysts’ updated eps estimates for Tuesday, May 24th: Central Garden & Pet (NASDAQ:CENTA) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $45.00 price target on the stock. According to Zacks, “Central Garden & Pet Company is a leading innovator, marketer […] ....

United States , Hong Kong General , Hong Kong , United Kingdom , San Diego , Las Vegas , Power Digital Infrastructure Acquisition Corp , Curiositystream Inc , Collplant Biotechnologies Ltd , Community Healthcare Trust , Collplant Holdings Ltd , Cellectar Biosciences Inc , Cardiol Therapeutics Inc , Central Garden Pet Company , Core Scientific Holding Co , Cv Sciences , Composecure Inc , Equities Research Analyst , Ceragon Networks , Zacks Investment Research , Novelos Therapeutics Inc , Cv Sciences Inc , Software Acquisition Group Inc , Ceragon Networks Ltd , Mtech Acquisition Corp , Community Healthcare Trust Incorporated ,

Cellectar Biosciences (NASDAQ:CLRB) Lifted to "Buy" at Zacks Investment Research

Cellectar Biosciences (NASDAQ:CLRB – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Tuesday, Zacks.com reports. The firm currently has a $0.50 target price on the biopharmaceutical company’s stock. Zacks Investment Research‘s price objective points to a potential upside of 42.05% […] ....

United States , Cellectar Biosciences , Morgan Stanley , Geode Capital Management , Zacks Investment Research , Novelos Therapeutics Inc , Cellectar Biosciences Inc , Franklin Resources Inc , York Mellon Corp , Capital Management , Cellectar Biosciences Company Profile Get Rating , Get Rating , Investment Research , Biosciences Inc , Novelos Therapeutics , New York Mellon Corp , Biosciences Company Profile , Nasdaq Clrb ,